Hologic (NASDAQ:HOLX) issued its earnings results on Wednesday. The medical equipment provider reported $0.63 EPS for the quarter, beating the Zacks’ consensus estimate of $0.61 by $0.02, Briefing.com reports. The firm had revenue of $852.40 million for the quarter, compared to analyst estimates of $836.91 million. Hologic had a positive return on equity of 27.62% and a negative net margin of 0.89%. Hologic’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.58 earnings per share.
NASDAQ:HOLX traded down $0.58 during trading hours on Friday, reaching $50.25. The company had a trading volume of 1,535,067 shares, compared to its average volume of 1,795,929. Hologic has a 1-year low of $37.47 and a 1-year high of $52.19. The company has a market capitalization of $13.74 billion, a price-to-earnings ratio of 22.53, a PEG ratio of 2.37 and a beta of 0.74. The stock has a 50 day moving average price of $48.47. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.02 and a current ratio of 1.45.
A number of equities research analysts recently commented on HOLX shares. BTIG Research reiterated a “buy” rating and issued a $52.00 target price on shares of Hologic in a research report on Thursday. Needham & Company LLC reiterated a “buy” rating and issued a $57.00 target price (up previously from $52.00) on shares of Hologic in a research report on Thursday. TheStreet upgraded Hologic from a “c+” rating to a “b” rating in a research report on Wednesday. Canaccord Genuity reiterated a “hold” rating and issued a $52.00 target price on shares of Hologic in a research report on Thursday. Finally, BidaskClub upgraded Hologic from a “hold” rating to a “buy” rating in a research report on Saturday, July 27th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $46.77.
In other Hologic news, insider Peter J. Valenti III sold 4,545 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $44.07, for a total value of $200,298.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.90% of the company’s stock.
A number of large investors have recently made changes to their positions in the business. CWM LLC raised its position in Hologic by 3,466.7% in the 2nd quarter. CWM LLC now owns 535 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 520 shares in the last quarter. Horan Capital Advisors LLC. acquired a new position in shares of Hologic in the 1st quarter valued at $33,000. First Interstate Bank acquired a new position in shares of Hologic in the 1st quarter valued at $40,000. Quadrant Capital Group LLC grew its holdings in shares of Hologic by 1,363.2% in the 1st quarter. Quadrant Capital Group LLC now owns 995 shares of the medical equipment provider’s stock valued at $47,000 after buying an additional 927 shares during the period. Finally, SevenBridge Financial Group LLC grew its holdings in shares of Hologic by 172.0% in the 2nd quarter. SevenBridge Financial Group LLC now owns 1,205 shares of the medical equipment provider’s stock valued at $58,000 after buying an additional 762 shares during the period. 96.45% of the stock is owned by institutional investors.
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Further Reading: Short Selling Stocks, A Beginner’s Guide
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.